3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Colorectal Neoplasms
2
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neutropenia
1
Febrile Neutropenia
1
Fatigue
1
Anemia, Iron-Deficiency
1
Anemia
1
Interventions
Filgrastim
6
pegylated granulocyte colony-stimulating factor
4
pegfilgrastim
4
Vancomycin
3
Etoposide
3
Cytarabine
3
Cefepime
3
Amikacin
3
Teicoplanin
2
Methotrexate
2
Meropenem
2
Granulocyte Colony-Stimulating Factor
2
Daunorubicin
2
Cyclosporine
2
Ciprofloxacin
2
Ceftazidime
2
ziprasidone
1
niraparib
1
lintuzumab
1
leridistim
1
fludarabine phosphate
1
angiotensin I (1-7)
1
Zolpidem
1
Warfarin
1
Vitamin B 12
1
Vincristine
1
Vecuronium Bromide
1
Transplantation
1
Tranexamic Acid
1
Tobramycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neutropenia
×
Sodium Chloride
×
Classical hematology
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts